AL

ALI LAKHANI

BIOGEN · WASHINGTON, DC · registered since 2024
Registered · LDAActive

At a glance

Registered since
2024
Senate LDA system
Clients
1
last 3 years
Filings
4
3 agencies contacted
Activity
filings by quarter
Works on

Background

Career
WASHINGTON, DC
2024 - present

Specific issues

Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing S.1214, RARE Act S.3558, BioSecure Act General issues regarding Priority Review Voucher Reauthorization, no specific bill number
Health Issues · 2024 Q4
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act S.3558, BioSecure Act
Health Issues · 2024 Q1

Clients

2024 · 4 filings
$██,███ / qtrUnlock

Filing history

2024 Q4
BIOGEN
Q4lda.gov →
2024 Q3
BIOGEN
Q3lda.gov →
2024 Q2
BIOGEN
Q2lda.gov →
2024 Q1
BIOGEN
Q1lda.gov →
Showing recent filings · full history on lda.gov